Particle-based platforms for malaria vaccines

被引:24
作者
Wu, Yimin [1 ]
Narum, David L. [1 ]
Fleury, Sylvain [2 ]
Jennings, Gary [3 ]
Yadava, Anjali [4 ]
机构
[1] NIAID, Lab Malaria Immunol & Vaccinol, Rockville, MD 20892 USA
[2] Mymetics Corp, CH-1066 Epalinges, Switzerland
[3] Cytos Biotechnol AG, CH-8952 Schlieren, Switzerland
[4] Walter Reed Army Inst Res, Malaria Vaccine Branch, US Mil Malaria Vaccine Program, Silver Spring, MD USA
关键词
Malaria; Vaccine; Particle; Delivery; Adjuvant; TRANSMISSION-BLOCKING VACCINE; AERUGINOSA EXOPROTEIN-A; IMMUNE-RESPONSES; ADJUVANT SYSTEM; THERAPEUTIC VACCINES; FALCIPARUM-MALARIA; EPITOPE DENSITY; IMMUNOGENICITY; CANDIDATE; DELIVERY;
D O I
10.1016/j.vaccine.2015.09.097
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recombinant subunit vaccines in general are poor immunogens likely due to the small size of peptides and proteins, combined with the lack or reduced presentation of repetitive motifs and missing complementary signal(s) for optimal triggering of the immune response. Therefore, recombinant subunit vaccines require enhancement by vaccine delivery vehicles in order to attain adequate protective immunity. Particle-based delivery platforms, including particulate antigens and particulate adjuvants, are promising delivery vehicles for modifying the way in which immunogens are presented to both the innate and adaptive immune systems. These particle delivery platforms can also co-deliver non-specific immunostimodulators as additional adjuvants. This paper reviews efforts and advances of the Particle-based delivery platforms in development of vaccines against malaria, a disease that claims over 600,000 lives per year, most of them are children under 5 years of age in sub-Sahara Africa. (C) 2015 Elsevier Ltd.
引用
收藏
页码:7518 / 7524
页数:7
相关论文
共 70 条
[11]  
Dinglasan RR, 2013, CURR MOL MED, V13, P479
[12]  
Ellis RD, 2010, HUM VACCINES, V6, P627
[13]   A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7 [J].
Fox, Christopher B. ;
Sivananthan, Sandra J. ;
Duthie, Malcolm S. ;
Vergara, Julie ;
Guderian, Jeffrey A. ;
Moon, Elliot ;
Coblentz, David ;
Reed, Steven G. ;
Carter, Darrick .
JOURNAL OF NANOBIOTECHNOLOGY, 2014, 12
[14]  
Fox Christopher B, 2013, Ther Adv Vaccines, V1, P7, DOI 10.1177/2051013613480144
[15]   TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses [J].
Fox, Christopher B. ;
Moutaftsi, Magdalini ;
Vergara, Julie ;
Desbien, Anthony L. ;
Nana, Ghislain I. ;
Vedvick, Thomas S. ;
Coler, Rhea N. ;
Reed, Steven G. .
VACCINE, 2013, 31 (49) :5848-5855
[16]   An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants [J].
Fox, Christopher B. ;
Haensler, Jean .
EXPERT REVIEW OF VACCINES, 2013, 12 (07) :747-758
[17]   Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines [J].
Fox, Christopher B. ;
Baldwin, Susan L. ;
Vedvick, Thomas S. ;
Angov, Evelina ;
Reed, Steven G. .
CLINICAL AND VACCINE IMMUNOLOGY, 2012, 19 (10) :1633-1640
[18]   Expression, purification and refolding of a self-assembling protein nanoparticle (SAPN) malaria vaccine [J].
Guo, Qin ;
Dasgupta, Debleena ;
Doll, Tais A. P. F. ;
Burkhard, Peter ;
Lanar, David E. .
METHODS, 2013, 60 (03) :242-247
[19]   Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation [J].
Hem, Stanley L. ;
HogenEsch, Harm .
EXPERT REVIEW OF VACCINES, 2007, 6 (05) :685-698
[20]  
Heppner DG, 2005, VACCINE, V23, P2243, DOI 10.1016/j.vaccine.2005.01.042